Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Gene therapy improves vision

After treatment with Luxturna, 93% of patients with an inherited retinal condition were able make their way through a maze in low to moderate light

Maze

Patients with the inherited retinal condition, Leber congenital amaurosis (LCA), showed improvements in their vision following gene therapy treatment.

Pioneering research revealed that 27 of the 29 patients who were treated with Spark Therapeutics’ Luxturna were able to navigate a maze in low to moderate light.

The results of the study were presented at the annual meeting of the American Academy of Ophthalmology (New Orleans, 11-14 November).

Patients in the study group also showed improvements in light sensitivity and peripheral vision.

Luxturna involves treatment with a viral vector that carries a healthy version of the gene into the retina.

In October, an advisory committee to the US Food and Drug Administration (FDA) endorsed the treatment. The FDA is expected to make a decision on Luxturna by January 2018.